Advanced

European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis

Wollenberg, Andreas ; Flohr, Carsten ; Simon, Dagmar ; Cork, Michael J. ; Thyssen, Jacob P. ; Bieber, Thomas ; de Bruin-Weller, Marjolein S. ; Weidinger, Stephan ; Deleuran, Mette and Taieb, Alain , et al. (2020) In Journal of the European Academy of Dermatology and Venereology : JEADV
Abstract

Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.1,2 Severely affected patients are often treated with immune-modulating systemic drugs.3,4 On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno-compromised, or have comorbidities. This also applies to AD patients on systemic immune-modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask... (More)

Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.1,2 Severely affected patients are often treated with immune-modulating systemic drugs.3,4 On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno-compromised, or have comorbidities. This also applies to AD patients on systemic immune-modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immune-modulating treatment of AD patients. The ETFAD decided to address some of these questions here.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
in press
subject
keywords
atopic dermatitis, COVID-19, immunosuppressant, SARS-CoV-2, systemic therapy
in
Journal of the European Academy of Dermatology and Venereology : JEADV
publisher
Elsevier
external identifiers
  • pmid:32223003
  • scopus:85083156285
ISSN
1468-3083
DOI
10.1111/jdv.16411
language
English
LU publication?
yes
id
83cd09e1-703e-4a1d-91e1-04f20ca62ce3
date added to LUP
2020-06-08 16:14:11
date last changed
2020-10-20 04:55:49
@article{83cd09e1-703e-4a1d-91e1-04f20ca62ce3,
  abstract     = {<p>Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.1,2 Severely affected patients are often treated with immune-modulating systemic drugs.3,4 On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno-compromised, or have comorbidities. This also applies to AD patients on systemic immune-modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immune-modulating treatment of AD patients. The ETFAD decided to address some of these questions here.</p>},
  author       = {Wollenberg, Andreas and Flohr, Carsten and Simon, Dagmar and Cork, Michael J. and Thyssen, Jacob P. and Bieber, Thomas and de Bruin-Weller, Marjolein S. and Weidinger, Stephan and Deleuran, Mette and Taieb, Alain and Paul, Carle and Trzeciak, Magdalena and Werfel, Thomas and Seneschal, Julien and Barbarot, Sebastien and Darsow, Ulf and Torrelo, Antonio and Stalder, Jean Francois and Svensson, Åke and Hijnen, Dirkjan and Gelmetti, Carlo and Szalai, Zsuzsanna and Gieler, Uwe and De Raeve, Linda and Kunz, Barbara and Spuls, Phyllis and von Kobyletzki, Laura B. and Fölster-Holst, Regina and Chernyshov, Pavel V. and Cristen-Zaech, Stéphanie and Heratizadeh, Annice and Ring, Johannes and Vestergaard, Christian},
  issn         = {1468-3083},
  language     = {eng},
  month        = {03},
  publisher    = {Elsevier},
  series       = {Journal of the European Academy of Dermatology and Venereology : JEADV},
  title        = {European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis},
  url          = {http://dx.doi.org/10.1111/jdv.16411},
  doi          = {10.1111/jdv.16411},
  year         = {2020},
}